CTIS2024-511921-75-00Active, not recruitingPhase 1
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE) - CRN00808-05
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 31
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •1. Completed one of the parent studies (Acrobat Evolve (CRN00808-02) or Acrobat Edge (CRN00808-03)), 2. Females must be non-pregnant and non-lactating either surgically sterile, post-menopausal, or using effective method(s) of birth control., 3. Willing to provide signed informed consent
Exclusion Criteria
- •1. Clinically significant concomitant disease including, but not limited to, cardiovascular disease; moderate or severe renal insufficiency; or significant liver disease (including cirrhosis), 10. Subjects with clinically significant abnormal findings during the Screening Period, and any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study, 2. Pituitary radiation since completing participation in parent studies, 3. History or presence of malignancy except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 year, 4. Positive test at Screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab)., 5. History of alcohol or substance abuse in the past 12 months, 6. Use of any investigational drug (other than paltusotine) within the past 30 days or 5 half-lives, whichever is longer before Screening, 7. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study., 8. Cardiovascular conditions or medications associated with prolonged QT or those which predispose subjects to heart rhythm abnormalities, 9. Subjects with symptomatic cholelithiasis
Investigators
Similar Trials
Unknown
Phase 2
ong-term study of LCZ696 treatment in patients with essential hypertensioJPRN-jRCT2080221787ovartis Pharma K.K.344
Unknown
Phase 3
Venlafaxine ER long-term extension study for major depressive disorderJPRN-jRCT2080221669Pfizer Japan Inc.50
Active, not recruiting
Phase 1
Extension study to evaluate the Safety of CB-03-01 1% cream applied twicedailyin subjects with Acne VulgarisFacial and truncal acne vulgarisMedDRA version: 20.0Level: LLTClassification code 10000519Term: Acne vulgarisSystem Organ Class: 100000004858EUCTR2015-002637-21-ROCASSIOPEA SpA609
Active, not recruiting
Phase 1
Extension study to evaluate the Safety of CB-03-01 1% cream applied twice daily in subjects with Acne VulgarisFacial and truncal acne vulgarisMedDRA version: 19.0 Level: LLT Classification code 10000519 Term: Acne vulgaris System Organ Class: 100000004858EUCTR2015-002637-21-BGCASSIOPEA SpA600
Active, not recruiting
Phase 1
An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17a-Propionate (CB-03-01) Cream, 1% Applied Twice-Daily in Subjects with Acne Vulgaris - not availableFacial and truncal acne vulgarisMedDRA version: 19.1Level: LLTClassification code 10000519Term: Acne vulgarisSystem Organ Class: 100000004858EUCTR2015-002637-21-PLCASSIOPEA SpA609